Systemic Inflammatory Response Syndrome Treatment Market Size, Share, and Industry Analysis, By Drug (Antimicrobials, Corticosteroids, and Others), By Indication (Infectious and Non-infectious), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Systemic inflammatory response syndrome (SIRS) refers to an inflated defense response from the body to a harmful stressor. The example of such stressors includes, infection, surgery, acute (sudden and severe) inflammation, ischemia (lack of blood flow to an area of your body), and cancers. It is a life-threatening medical emergency that causes severe inflammation throughout the body. This can also lead to reversible or irreversible organ failure and even death. The symptoms of SIRS include redness and swelling (edema) of affected parts of the body, extreme pain, intense fatigue, tachycardia, loss of consciousness, and many others. Furthermore, the treatment largely depends on the underlying cause. Still, it may include antibiotics for bacterial infection, vasopressors for the control of hypertension, IV insulin for the management of blood sugar levels, and corticosteroids to prevent or reverse the septic shock.

The growing prevalence of several types of bacterial infections, including bacterial sepsis, urinary tract infections, and many others, is expected to boost the market growth during the forecast period.

• For instance, as per the data provided by the World Health Organization (WHO) in May 2024, sepsis is one of the most frequent causes of death worldwide. As of 2020, nearly 48.9 million cases of sepsis occurred throughout the world.

In addition, the rise in antibiotic resistance, the growing number of immunocompromised patients, and the increase in the number of severe burns and trauma cases are some of the causes contributing to the increased incidence of systemic inflammatory response syndrome. As a result, there is an increasing demand for effective treatments to manage inflammatory responses and halt the spread of the disease.

The COVID-19 pandemic had a positive impact on the global systemic inflammatory response syndrome treatment market in 2020. This was mainly due to a rise in the number of hospital-acquired infections and conditions such as sepsis, which can trigger the SIRS. The surge in the number of cases of hospital-acquired infections was further driven due to the hospitalizations caused by the coronavirus pandemic.

• For example, as per the data provided by the JAMA Network Open, in September 2023, sepsis associated with the SARS-CoV-2 infection was more lethal than bacterial sepsis during the early period of the COVID-19 pandemic. SARS-CoV-2 was responsible for nearly one in six sepsis cases during the first 33 months of the COVID-19 pandemic.

Therefore, the COVID-19 pandemic significantly increased the incidence of severe inflammatory responses, highlighting the need for effective management and treatment options.

Segmentation

Key Insights

The following key insights are covered in the report:

• Epidemiology of Systemic Inflammatory Response Syndrome


• Pipeline Analysis By Key Players


• New Product Launches By Key Players


• Key Industry Developments (Mergers, Acquisitions, Partnerships)


• Impact of COVID-19 on the Market

Analysis by Drug

Based on the drug, the market can be segmented into antimicrobials, corticosteroids, and others.

The antimicrobials segment held a significant market share in 2023. The growth of the segment is attributed to the increasing number of clinical trials and the launches of medications for the treatment of several medical conditions that trigger SIRS, including acute pancreatitis, bacterial infection, and blood cancers.

• For instance, in April 2024, CalciMedica Inc., a clinical-stage biopharmaceutical company, announced that it had started the phase 2b CARPO trial of Auxora for the treatment of acute pancreatitis (AP).

Furthermore, the corticosteroids segment is anticipated to grow at a significant growth rate in the coming years. The segmental growth is mainly driven by the fact that several industry players and research universities are initiating clinical trials for the development of medicines for the treatment of systemic inflammatory response syndrome. Also, some of the research institutes are conducting clinical trials to evaluate the efficacy of steroids in reducing postoperative systemic infection for patients undergoing different types of surgeries.

• For instance, as per the data provided by ClinicalTrials.gov, Duke University initiated a phase 3 clinical trial in October 2017 to evaluate the efficacy of steroids in the reduction of systemic inflammation after infant heart surgery. This study was completed in March 2022, and the findings demonstrated the benefits of steroids in the reduction of postoperative inflammation.

Regional Analysis

Based on region, the systemic inflammatory response syndrome treatment market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for a major share of the global systemic inflammatory response syndrome treatment market in 2023 and is expected to grow at a significant CAGR during the forecast period. The growth of the region is mainly due to the growing prevalence of systemic inflammatory response syndrome (SIRS), leading to an increasing demand for medications used in the treatment of this disorder in the region.

In addition, increasing government initiatives to raise awareness of infectious and non-infectious diseases, a surge in the geriatric population that is at a higher risk of hospitalization, and a higher number of industry players in North America focusing on receiving regulatory approvals to introduce novel treatments for infectious diseases are some of the factors boosting the market in the region.

• For example, in April 2024, the U.S. Food and Drug Administration (FDA) approved Zevtera (Ceftobiprole Medocaril Sodium injection) for the treatment of adults with Staphylococcus aureus bloodstream infections (bacteremia).

Furthermore, Europe accounted for a substantial market share in 2023. The well-developed healthcare infrastructure enhances the systemic inflammatory response syndrome treatment market in the region. The market growth is driven by the rising prevalence of SIRS and growing awareness about the disease. Also, increasing cases of burns, cirrhosis, vasculitis, transfusion reactions, and hemorrhagic shocks, which cause systemic inflammatory response syndrome, is another additional factor driving the market growth during the forecast period in the region.

Key Players Covered

The profiles of key players, such as Innoviva Specialty Therapeutics, GSK plc., Pfizer Inc., AdrenoMed AG, Cipla, and CalciMedica Inc., are included in the report.

Key Industry Developments

• In April 2024, AdrenoMed AG announced that the U.S. Food and Drug Administration (FDA) granted fast-track designation to its product candidate Enibarcimab, a non-neutralizing monoclonal antibody, for the treatment of septic shock.


• In April 2024, GSK plc. announced the positive outcomes of the pivotal EAGLE-1 phase III trial of Gepotidacin, a potential oral antibiotic with a novel mechanism of action for uncomplicated urogenital gonorrhea (GC) in adolescents and adults.


• In September 2023, researchers from Korea University and Yonsei University College of Medicine demonstrated the efficacy of the RIPK3-mediated necroptosis inhibitor in the treatment of systemic inflammatory syndrome.  


• In December 2021, CalciMedica, Inc. announced that it had completed a phase 2 study of CM4620 Injectable Emulsion in patients with acute pancreatitis and accompanying systemic inflammatory response syndrome (SIRS).